• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Rationale & Ben

  2026-05-21

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) is a synthetic, modified mRNA designed for robust, reproducible bioluminescent reporting in gene expression and cell viability assays. Key optimizations—ARCA capping and modified nucleotides—reduce immunogenicity and improve stability, as demonstrated in recent peer-reviewed studies. This article details the mechanistic rationale, evidence base, and workflow parameters for best-in-class experimental controls.

• Ezh2–p53 Competition Regulates lncRNA Neat1 and Inflammasome

  2026-05-20

  This study uncovers a non-canonical, methyltransferase-independent role for Ezh2 in promoting inflammasome activation via regulation of lncRNA Neat1 transcription. The findings reveal a competitive interaction between Ezh2 and p53 at the Neat1 promoter, advancing understanding of epigenetic regulation in innate immunity and inflammation.

• Dehydroabietic Acid: Precision Tools for Adipocyte-Targeted

  2026-05-20

  This article explores how Dehydroabietic acid, a dual PPAR-α/γ agonist, is reshaping translational research strategies in the context of adipocyte-targeted metabolic modulation. Drawing on cutting-edge evidence, including CRISPR-based advances and new delivery paradigms, we examine the mechanistic rationale, experimental validation, and protocol optimization for translational teams. The discussion bridges metabolic pathway insights with practical workflow guidance, highlighting how APExBIO’s high-purity Dehydroabietic acid uniquely enables the next generation of precise metabolic disorder research.

• Thioredoxin System Modulates Chk1 Inhibitor Sensitivity in N

  2026-05-19

  This study uncovers how the thioredoxin (Trx) antioxidant system governs cancer cell sensitivity to Chk1 inhibitors through redox-mediated regulation of ribonucleotide reductase. By linking Trx-driven redox control to deoxynucleotide synthesis and identifying synergistic drug combinations, the research provides a mechanistic basis for optimizing Chk1 inhibitor deployment in non-small cell lung cancer models.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis S

  2026-05-19

  Anlotinib hydrochloride, a potent multi-target tyrosine kinase inhibitor, empowers researchers to dissect angiogenesis and tumor growth with precision. Its superior selectivity and low cytotoxicity enable reproducible endothelial cell assays and in vivo modeling, streamlining cancer research workflows.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-05-18

  This study reveals that HOXC8 inhibits pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by repressing caspase-1 expression through recruitment of HDAC1/2 to the CASP1 promoter. The findings clarify a novel transcriptional mechanism for immune and cell death regulation in lung cancer, providing a foundation for targeted research on pyroptosis modulation.

• I-BET-762: A Selective BET Inhibitor for Epigenetic Research

  2026-05-18

  I-BET-762 is a potent and selective BET inhibitor that targets the acetyl-lysine binding pocket of BET proteins with nanomolar affinity. It demonstrates robust transcriptional repression of LPS-inducible genes and enhances ferroptosis in preclinical cancer models. This article details its mechanism, key benchmarks, and integration in inflammation and cancer biology research.

• EGCG Nanoparticles Enhance FLASH-RT via ROS and Immune Modul

  2026-05-17

  This study demonstrates that functionalized EGCG nanoparticles (BENPs) significantly augment the antitumor efficacy of ultra-high dose rate radiotherapy (FLASH-RT) by promoting reactive oxygen species (ROS) generation and immune activation. The findings clarify the mechanistic basis for improved radiosensitization and provide a translational strategy for cancer therapy optimization.

• Nicotine Signaling in CKD Progression: Evidence and Mechanis

  2026-05-16

  This review elucidates how nicotine signaling, specifically via non-neuronal nicotinic acetylcholine receptors (nAChRs), accelerates chronic kidney disease (CKD) progression in smokers. The findings clarify the mechanistic interplay between nicotine exposure, renal oxidative stress, and fibrosis, suggesting new experimental directions for antioxidant bioactive compounds in renal research.

• Tacrine Hydrochloride Hydrate: Scaffold Innovations in Alzhe

  2026-05-15

  Explore how Tacrine hydrochloride hydrate advances Alzheimer's disease research as a foundational scaffold for next-generation therapeutics. This article offers a deep scientific analysis of its mechanism, neuroprotective roles, and hybrid molecule opportunities, uniquely contextualizing its value beyond standard assay protocols.

• Dendritic Cell-Mediated Delivery of Amikacin into Mycobacter

  2026-05-15

  This study introduces a cell-mediated approach for targeted amikacin (BAY416651) delivery into granulomas in a mouse model of Mycobacterium avium infection. By using monocyte-derived dendritic cells as carriers, the researchers demonstrated localized antibiotic concentration within granulomatous tissue, offering a strategy to enhance efficacy while minimizing systemic toxicity. The findings advance antibiotic resistance research by illustrating a method to overcome barriers to drug penetration in persistent mycobacterial infections.

• Dabigatran (Pradaxa): Applied Workflows for Thrombin Inhibit

  2026-05-14

  Dabigatran (Pradaxa) from APExBIO enables reproducible thrombin inhibition assays and advanced coagulation function tests. This article details experimental workflows, troubleshooting strategies, and the latest literature-backed innovations for stroke and thrombosis research.

• Guarding the Phosphorylation Code: Translational Imperatives

  2026-05-14

  Preserving protein phosphorylation is critical for decoding cellular signaling, especially in translational research targeting neurodegeneration and aging. This article synthesizes mechanistic insights, competitive context, and actionable guidance for researchers, spotlighting APExBIO’s Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) as a cornerstone of reproducible, high-impact discovery.

• Tofacitinib (CP-690550): Optimizing Immune Modulation Assays

  2026-05-13

  Tofacitinib (CP-690550) unlocks precise cytokine signaling blockade and mitochondrial repair in RA macrophage models, outperforming anti-TNF and metabolic inhibitors. This article translates the latest mechanistic breakthroughs into actionable assay workflows, troubleshooting, and advanced immune modulation strategies.

• MTT: Benchmark Tetrazolium Salt for In Vitro Cell Viability

  2026-05-13

  Unlock robust, quantitative measurement of cell proliferation and metabolic activity with MTT, the gold-standard colorimetric assay reagent. See how recent angiogenesis research and expert troubleshooting optimize its use across diverse biomedical workflows.

444 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page